Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.52 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21564268 | 0.81 | DCPS (0.53) | ALDH1A1HPGDHSD17B10NUDT1CYP1A2 | |
| SCHEMBL30945013 | 0.81 | DCPS (0.57) | ALDH1A1HPGDHSD17B10NUDT1CYP1A2 | |
| SCHEMBL179260 | 0.78 | LMNA (0.49) | ALDH1A1HPGDHSD17B10NUDT1CYP1A2 | |
| SCHEMBL10139179 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL12142339 | 0.78 | GPR3 (0.54) | ALDH1A1HPGDHSD17B10NUDT1CYP1A2 | |
| SCHEMBL21250575 | 0.77 | ATM (0.43) | ALDH1A1HPGDHSD17B10CYP1A2KDM4E | |
| SCHEMBL29069929 | 0.77 | HSD17B10 (0.57) | ALDH1A1HPGDHSD17B10NUDT1CYP1A2 | |
| SCHEMBL29730774 | 0.77 | HSD17B10 (0.57) | ALDH1A1HPGDHSD17B10NUDT1CYP1A2 | |
| SCHEMBL19261285 | 0.77 | ATM (0.43) | ALDH1A1HPGDHSD17B10NUDT1CYP1A2 | |
| SCHEMBL10063491 | 0.77 | KDM4E (0.49) | ALDH1A1HPGDHSD17B10CYP1A2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-06-16 | — | — | US | disclosed |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | ARAXES PHARMA LLC (US) | 2022-03-22 | — | — | US | disclosed |
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | ARAXES PHARMA LLC (US) | 2019-08-13 | — | — | US | disclosed |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-05-10 | — | — | US | disclosed |
| WO-2018068017-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2018-04-12 | — | — | WO | disclosed |
| US-9718815-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-08-01 | — | — | US | disclosed |
| US-9315505-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8969363-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8901133-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2014-10-02 | — | — | US | disclosed |
| US-8785454-B2 | Heterocyclic compounds and uses thereof | INTELLIKINE LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. | 2012-12-27 | — | — | US | disclosed |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377743-B2 | Inhibitors of RAS and methods of use thereof | KRAS, NRAS, HRAS | ALDH1A1 4072/4885HPGD 2154/4885HSD17B10 4693/4885 |
| US-20150126506-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3154/4885HPGD 836/4885HSD17B10 1927/4885 |
| US-20150031672-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3154/4885HPGD 836/4885HSD17B10 1927/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3154/4885HPGD 836/4885HSD17B10 1927/4885 |
| US-20120122838-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3154/4885HPGD 836/4885HSD17B10 1927/4885 |
| US-20220185792-A1 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | ALDH1A1 4228/4885HPGD 4133/4885HSD17B10 2879/4885 |
| US-11358959-B2 | Benzothiophene and benzothiazole compounds and methods of use thereof | KRAS, NRAS, RB1 | ALDH1A1 959/4885HPGD 3921/4885HSD17B10 3652/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 1402/4885HPGD 1422/4885HSD17B10 4086/4885 |
| US-20180127396-A1 | INHIBITORS OF RAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | ALDH1A1 4303/4885HPGD 2090/4885HSD17B10 4683/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | ALDH1A1 4228/4885HPGD 4133/4885HSD17B10 2879/4885 |
| US-11279689-B2 | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer | KRAS, NRAS, HRAS | ALDH1A1 1729/4885HPGD 1780/4885HSD17B10 3857/4885 |
| US-20140296207-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, AKT3, PIK3CD | ALDH1A1 3577/4885HPGD 855/4885HSD17B10 2578/4885 |
| US-20120329776-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 3050/4885HPGD 517/4885HSD17B10 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.